New Genomic Test Reduces Need for Chemotherapy in Breast Cancer Patients
Revolutionary test spares millions of cancer patients from chemotherapy
The Independent
Image: The Independent
A groundbreaking genomic test, Prosigna, may eliminate the need for chemotherapy in millions of breast cancer patients. The Optima trial, involving over 4,400 participants, demonstrated that those with low Prosigna scores could effectively be treated with hormone therapy alone, achieving survival rates comparable to those receiving chemotherapy.
- 01The Prosigna test identifies gene activity in breast cancer patients.
- 02In the Optima trial, over 4,400 participants aged 40 or older were studied.
- 03Patients with low Prosigna scores received only hormone therapy, while high scorers received both chemotherapy and hormone therapy.
- 04Five years post-treatment, 93.6% of low-scoring patients were alive and recurrence-free, similar to 94.8% of those who underwent chemotherapy.
- 05This test could significantly change treatment protocols for hormone-sensitive breast cancer.
Advertisement
In-Article Ad
A new genomic test, Prosigna, has shown potential to spare millions of breast cancer patients from undergoing chemotherapy, according to findings from the Optima trial. This study involved more than 4,400 participants aged 40 and older with hormone-sensitive breast cancer. Those with a low Prosigna score, indicating low gene activity, were treated solely with hormone therapy. In contrast, patients with high scores received both chemotherapy and hormone therapy. Remarkably, five years after treatment, 93.6% of the low-scoring patients were alive and recurrence-free, a result comparable to the 94.8% survival rate of those who underwent chemotherapy. This advancement could significantly alter treatment strategies for breast cancer.
Advertisement
In-Article Ad
This test could lead to fewer patients undergoing chemotherapy, reducing side effects and healthcare costs.
Advertisement
In-Article Ad
Reader Poll
Do you think genomic testing should be widely adopted in cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.